ArticleMolecular biomedicine2026
Circulating cell-free DNA profiling reveals ancestry-dependent genetic variation in metastatic prostate cancer.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African American men experience markedly higher prostate cancer incidence and mortality yet remain underrepresented in genomic studies aimed at identifying ancestry-associated molecular drivers of disease progression. Circulating cell-free DNA (cfDNA) provides a minimally invasive means of capturing tumor-derived genomic alterations and enables broad characterization of molecular heterogeneity. In this study, we performed comprehensive plasma cfDNA profiling in 22 African American and 66 Caucasian men with metastatic castration-resistant prostate cancer (mCRPC) to define ancestry-related differences in mutation landscapes. Across samples, we identified 281 variants within 88 genes, with African American patients exhibiting a significantly higher burden of differentially frequent mutations. Integration of Gene Ontology analysis, KEGG pathway mapping, and functional enrichment revealed ancestry-dependent perturbations in pathways central to prostate cancer biology, including PI3K-AKT, MAPK, androgen signaling, DNA repair, and cell-cycle regulation. A panel of 25 genes emerged as key contributors to divergent disease mechanisms across racial groups. Several variants enriched in African American patients involved genes regulating genomic stability and treatment resistance, offering potential insight into observed clinical outcome disparities. These findings provide a comprehensive, ancestry-informed cfDNA mutational landscape in mCRPC and highlight biologically meaningful differences that may support the development of non-invasive biomarkers, improved risk stratification, and ancestry-tailored precision oncology strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.